Global Leading Market Research Publisher QYResearch announces the release of its latest report *”Hemocoagulase – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″*. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Hemocoagulase market, including market size, share, demand, industry development status, and forecasts for the next few years.
For surgeons, emergency physicians, and wound care specialists, uncontrolled bleeding from surgical incisions, traumatic wounds, or mucosal surfaces (epistaxis, dental extraction, GI bleeding) remains a critical challenge. Traditional methods – pressure, ligation, electrocautery, absorbable gelatin sponges – can be ineffective for diffuse oozing or inaccessible sites. Hemocoagulase products directly address this through topical hemostatic enzymes (thrombin-like snake venom enzymes) that accelerate clot formation by converting fibrinogen directly to fibrin, bypassing the coagulation cascade. Applied as powder (solid) or solution (liquid) to bleeding surfaces, these agents provide rapid hemostasis, reduce intraoperative blood loss, and minimize need for sutures or cautery. The global market for Hemocoagulase was estimated to be worth USmillionin2025andisprojectedtoreachUSmillionin2025andisprojectedtoreachUS million, growing at a CAGR of % from 2026 to 2032.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/5975080/hemocoagulase
Understanding Hemocoagulase: Topical Hemostatic Enzymes
Hemocoagulase (also known as hemocoagulase, batroxobin, reptilase) is a serine protease enzyme isolated from snake venom (Brazilian lancehead pit viper Bothrops atrox or Bothrops moojeni). Mechanism: Enzymatically converts fibrinogen to fibrin (clot) without activating factor XIII – forming a loose, degradable fibrin clot susceptible to plasmin (physiological fibrinolysis) within 24-48 hours. Unlike thrombin (bovine/human recombinant), hemocoagulase does not activate platelets or factor XIII. Advantages:
- Topical application only – not for systemic use (risk of thrombosis, anaphylaxis). Applied as dry powder (spray, insufflation) or liquid (soaked gauze, spray).
- Rapid onset – hemostasis within 1-5 minutes (fibrin formation). Effective for capillary, venous, small arterial bleeding.
- No heat generation – unlike electrocautery, no thermal tissue damage.
- Biodegradable – fibrin clot resorbs within days.
- Cost-effective – compared to thrombin (bovine thrombin can induce antibodies cross-reacting with human factor V – bleeding risk).
Clinical indications (approved in China, other Asian countries; not FDA approved in US):
- General bleeding: mucosal bleeding (epistaxis – nosebleeds, oral surgery – post-extraction, GI endoscopic bleeding – post-polypectomy, minor ulcer bleeding), dermatological procedures (shave biopsies, excisions), hemorrhoids (post-operative).
- Emergency bleeding: traumatic wounds (lacerations, abrasions), emergency department procedures (suture placement assistance, control oozing).
- Surgery: diffuse capillary oozing during surgery (hepatic, splenic, renal, thoracic), anastomotic bleeding (vascular, bowel), bone surface bleeding (spinal, orthopedic). Applied as spray/powder.
- Others: dental clinics (post-extraction, periodontal surgery), urology (prostate biopsy), gynecology (cervical biopsy, LEEP).
Market Segmentation by Formulation
- Solid (Powder, Dominant, ~60-65% of market value): Lyophilized hemocoagulase powder in vials (5-10 KU – Kunit units). Reconstituted with sterile water or saline? Actually powder applied directly to bleeding site (dry), not reconstituted. Spray bottle attachment (insufflator) for endoscopic applications (GI, bronchial). Used for diffuse bleeding (abrasions, oozing surfaces), convenient to apply. Advantages: long shelf life (2-3 years room temperature), no cold chain, easy to carry in emergency kits, no preparation time. Storage: room temperature (<25°C). Major market share in military/trauma kits, ambulatory surgery centers, outpatient clinics.
- Liquid (Solution, ~35-40% of market value): Hemocoagulase dissolved in sterile buffer (vial or ampoule, ready-to-use). Spray bottle, dropper, or soaked gauze. Applied directly. Advantages: no reconstitution required, convenient for endoscopic use (spray catheter), uniform coverage. Disadvantages: shorter shelf life (1-2 years), refrigeration recommended (some heat-stable formulations). Hospital operating rooms, endoscopy suites prefer liquid (ready-to-use, no powder aerosolization risk). Smaller market share but growing (convenience).
Market Segmentation by Application
- Surgery (Largest, ~45-50% of market value): General surgery (abdominal, hepato-biliary, gastrointestinal, urologic, gynecologic), cardiovascular (diffuse oozing from bypass graft sites), orthopedic (bone surface, spinal decompression), neuro (dura, brain surface). Hemocoagulase used when: oozing from raw surfaces (liver resection bed, splenic laceration), oozing after vessel ligation but not amenable to suture/electrocautery, patient on antiplatelet/anticoagulant (aspirin, clopidogrel, warfarin, DOACs), high risk of rebleeding. Applied as powder spray or liquid-soaked gauze. Surgical highest volume due to OR caseload (millions surgeries annually). China leading.
- General Bleeding (Non-urgent) (~25-30%): Dental clinics (post-extraction bleeding – <2% of extractions have prolonged bleeding, hemocoagulase soaked gauze), ENT (epistaxis – cotton pledget), dermatology (post-shave biopsy, excision), gastroenterology (post-polypectomy bleeding prevention – sprayed via endoscope). Outpatient procedures. General bleeding share stable.
- Emergency Bleeding (Smaller but Critical) (~15-20%): Trauma (lacerations, abrasions), emergency department (control bleeding while preparing suture, minimize blood loss). Mass casualty situations, military field hospitals. Powder formulation spray (compact, portable). Emergency bleeding share lower volume but high acuity, essential.
- Others (Veterinary, dentistry, etc.) (~5-10%): Veterinary surgery (hemostatic agent for small animals, equine). Dentistry (periodontal surgery). Not significant.
Competitive Landscape and Exclusive Market Observation (2025–2026)
Key Players: Avanc Pharmaceutical (Chinese, hemocoagulase for injection (powder) – brand name? One of major suppliers to Chinese hospitals. Domestic market leader estimate 30-35% share. Konruns Pharmaceutical (Chinese manufacturer, hemocoagulase powder, also liquid formulations. Domestic hospital and export to SE Asia, Africa. Zhaoke Hefei (subsidiary of Zhaoke Pharmaceutical, hemocoagulase products, solid and liquid, China hospital sales). Penglai Nuokang Pharmaceutical (Chinese, hemocoagulase (powder). Tobishi Pharmaceutical (Chinese, hemocoagulase powder, spray, liquid).
Exclusive Industry Insight (H1 2026): Hemocoagulase market is China-centric with limited international presence:
- Regulatory: Hemocoagulase approved in China (NMPA), Japan, South Korea, India, Vietnam, Indonesia, Brazil, some Middle East countries. Not approved in US (FDA), Canada, Europe (EMA), Australia, because bovine thrombin (FDA approved) and recombinant human thrombin (pricing, availability) available. US uses topical hemostats: gelatin sponges (Gelfoam), oxidized cellulose (Surgicel), microfibrillar collagen (Avitene), thrombin (bovine, human recombinant flowable sealants).
- Pricing: China domestic products affordable (¥50-200 per unit). Hospital procurement uses volume-based purchasing. Price erosion limited.
- Demographic drivers: China aging population (surgical volume increases), trauma, emergency, dental care. Hemocoagulase standard in Chinese ORs, EDs. Many smaller cities, rural clinics use (low cost, effective).
- Competitive landscape: Top 5 players (Avanc, Konruns, Zhaoke, Penglai Nuokang, Tobishi) dominate China market (>80% share). Fragmentation. No multinational competitors (Sysmex? no). Niche.
User case: Peking Union Medical College Hospital (2025) – Hemocoagulase powder used in hepatobiliary surgery (liver resection). Diffuse oozing from cut surface (liver parenchyma). Sprayed directly, achieves hemostasis in 2-3 minutes, reduces blood transfusion requirement, no thermal injury. Expense minimal (¥100-200 per case). Surgeon preference.
User case 2: Emergency department, Shanghai (2025) – Patient with bleeding laceration (arm, 4 cm). Irrigation, local anesthetic. Hemocoagulase soaked gauze applied (3 minutes). Bleeding stopped, sutures placed (less blood in field). No cautery needed. Discharge same day.
Technical Deep Dive: Hemocoagulase vs. Thrombin
| Feature | Hemocoagulase | Thrombin (bovine/human) |
|---|---|---|
| Source | Snake venom | Bovine plasma or recombinant |
| Mechanism | Fibrinogen → fibrin (weak clot) | Fibrinogen → fibrin (stronger, crosslinked by factor XIII) |
| Antigenicity | Low (snake) | Bovine thrombin causes antibody formation, cross-reacts with human factor V (bleeding risk) |
| FDA approval | No | Yes (several) |
| Cost | Low (China generic) | High (recombinant) |
Safety: Hypersensitivity (rare). Use caution if snake venom allergy? not contraindicated.
Future Outlook (2026–2032): Drivers and Challenges
Growth Drivers:
- Asia surgical volume growth: China performing 80 million surgeries annually (2025 forecast), India 30 million. Hemocoagulase established standard in many specialties.
- Aging population: Elderly more likely to be on antiplatelets/anticoagulants (aspirin, clopidogrel, warfarin, DOACs). Topical hemostatic agents reduce bleeding risk.
- Emergency and trauma: Urbanization, road traffic accidents, workplace injuries. Hemocoagulase portable, rapid.
Constraints:
- Limited Western acceptance: US/Europe not adopting (regulatory, existing products). International market growth limited.
- Recombinant thrombin competition: Higher cost but superior efficacy (faster, stronger clot). Hospitals in wealthy Asia (Japan, South Korea, Singapore) may switch.
Emerging: Hemocoagulase combination products (powder with collagen, gelatin matrix). Not current.
The market projected volume CAGR 4-6% (China, India, SE Asia). Value CAGR 3-5% (price stable). China dominates. International expansion highly unlikely.
Contact Us
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666 (US)
JP: https://www.qyresearch.co.jp
